Advertisement

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Gerrit J. Schuurhuis, Michael Heuser, Sylvie Freeman, Marie-Christine Béné, Francesco Buccisano, Jacqueline Cloos, David Grimwade, Torsten Haferlach, Robert K. Hills, Christopher S. Hourigan, Jeffrey L. Jorgensen, Wolfgang Kern, Francis Lacombe, Luca Maurillo, Claude Preudhomme, Bert A. van der Reijden, Christian Thiede, Adriano Venditti, Paresh Vyas, Brent L. Wood, Roland B. Walter, Konstanze Döhner, Gail J. Roboz and Gert J. Ossenkoppele

Publisher's Note: There is a Blood Commentary on this article in this issue.

Abstract

Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.

  • Submitted September 5, 2017.
  • Accepted January 3, 2018.
View Full Text